Skip to main content
UKPMC Funders Author Manuscripts logoLink to UKPMC Funders Author Manuscripts
. Author manuscript; available in PMC: 2022 Sep 3.
Published in final edited form as: Semin Pediatr Neurol. 2018 Jun 20;27:10–15. doi: 10.1016/j.spen.2018.03.002

Global Burden of Pediatric Neurological Disorders

Charles Richard Newton 1,
PMCID: PMC7613506  EMSID: EMS153427  PMID: 30293585

Abstract

Neurological conditions in children represent a significant proportion of the global burden of disease, since they contribute to premature mortality and years lived with disability. The burden of neurological conditions, as measured by the total disability adjusted live years has decreased significantly over the last 25 years (1990-2015), mainly due to the reduction in the mortality, as the years lived with disability has increased slightly. However, in some regions of the world, notably South Asia and sub-Saharan Africa, the burden remains high, driven by the high incidence of prematurity, neonatal encephalopathy and infections of the central nervous system.

Introduction

The burden of disease is the impact of a health condition, measured by epidemiological methods, quality of death or financial costs. It allows comparisons of diseases and conditions between the sexes, different age groups, geographical areas, and chart secular trends. It is used for advocacy, identifying high-risk populations, prioritizing actions in health, planning preventive measures, assessing healthcare systems, and interventions. Neurological disorders in children have received relatively little attention in the global burden of disease (GBD), but given their incidence and years lived with a disability, these conditions are likely to have a significant contribution to the GBD.

Measurement

The standard epidemiological measures such as prevalence (ie, the number of cases identified at a particular point or sometimes over a period, that is, period prevalence) divided by the denominator, incidence (number of new cases per unit time) and mortality provide useful data, but do not describe the full impact of neurological conditions, particularly for morbidity and disability.

To provide a more encompassing measure of the effect of conditions, disability adjusted life years (DALY) were devised in the 1990s to measure the GBD.1 The DALY is a single value for a condition to facilitate comparisons between geographical area, ages, and time periods. It was based upon 4 principles: (1) inclusion of health outcomes that represent a loss of welfare; (2) characteristics of the individual affected by a health outcome are restricted to age and sex, since these demographic variables are most reliably recorded; (3) consider health outcomes equal throughout the world, that is, a life is worth the same throughout the world; and (4) time is the unit of measurement, since it can be applied to many different conditions.2

The DALY consists of 2 components: the years of life lost due to premature death (YLL) and the years of life living in states of poor health or disability (YLD). The YLD is derived from the number of years, the incidence (originally) and the disability weighting (DW):

YLD=yearslivingwithdisability×incidence/prevalence×DW.

The incidence was originally used because: (1) the method of calculating time lived with disabilities is more consistent with the method for calculating time lost due to premature mortality; (2) incidence is more sensitive to epidemiological trends and more sensitive to the impact of health interventions; and (3) incidence provides more internal consistency than prevalence data.2 However, since there is less data on the incidence of many disorders, the most recent calculations have been based on prevalence data.3,4

Initially, the DW were derived from expert opinion, but in the most recent calculations of DALYs, the DW have been based upon empirical data from surveys conducted 5 countries across the world.5 So for example, the DW for epilepsy are treated, seizure free 0.072 (95% cCI: 0·047-0·106); treated, with recent seizures 0.319 (0.211-0·445); untreated 0.420 (0.279-0.572); and severe 0.657 (0.464-0.827).

One DALY can be considered as 1 lost year of “healthy” life. The total DALY for a condition is simply the sum of YLL and YLD:

DALY=YL+YLD.

The data can be represented as total DALYs, proportion of total DALYs (%) for each condition or per capita, usually expressed as per 100,000 of the population.

The quality-adjusted life-years (QALY) was introduced in the 1970s, and this measure takes into account both quantity and the quality of life. It is a measure of the life expectancy corrected for loss of quality of that life caused by disorders. A year of normal health is given a QALY of 1 while a year of complete functional impairment (eg, death) has a QALY of 0. This measure is often used to measure the effect of medical interventions, and has not been applied to many pediatric neurological disorders, with the exception of epilepsy6 and head injury.7

Global Burden of Disease

There have been few publications specifically on the GBD of neurological disorders. In most articles neurological conditions were combined with mental health conditions. In 2010, mental, neurological, and substance use disorders accounted for 10.4% of global DALYs, 2.3% of global YLLs, and 28.5% of global YLDs.8 Mental disorders accounted for the largest proportion of DALYs (56.7%), followed by neurological disorders (28.6%), and substance use disorders (14.7%). DALYs peaked in early adulthood for mental and substance use disorders but were more consistent across age for neurological disorders.

In the GBD 2015,9 the DALYs of nondegenerative neurological conditions represents a significant proportion of the total DALYs in the pediatric age range (Fig. 1). Overall, the proportion is approximately 15% for neurological conditions across all age groups, but insults to the central nervous system (CNS) account for over 40% of the DALYs in neonates, mainly due to the effect of prematurity and hypoxic-ischemic encephalopathy. Neurological conditions have a greater burden than the common mental health disorders, that is, autism and ADHD.

Figure 1.

Figure 1

Contribution of nondegenerative neurological conditions to GBD as a percentage of DALYs in 2015. (Color version of the figure available online.)

Most of this burden is accounted by death, as the YLD from these disorders is under 10% (Fig. 2). In older children, CNS infections are a significant burden (Figs. 1 and 2), even though these figures do not include the CNS involvement of the major infections such as HIV, malaria and tuberculosis, nor traumatic head injuries.

Figure 2.

Figure 2

Contribution of nondegenerative neurological disorders to GBD as measured by YLD in 2015 in all ages. (Color version of the figure available online.)

Globally there have been significant changes in the burden of neurological conditions in children from the initial estimated in 1990 and those in 2015. The total number of DALYs attributed to neurological disorders in children has decreased, with particular marked reduction in DALYs associated with prematurity (57% reduction); but less with hypoxic-ischemic encephalopathy (23% reduction) in the under 5 year olds (Fig. 3).

Figure 3.

Figure 3

Years lived with disability of children (under 5 years) with neurological disorders from 1990-2015. (Color version of the figure available online.)

In the 5-14 year olds the survival of those with neonatal encephalopathy has increased the burden from 1990-2015 (35% increase), but there have been significant reduction in the burden caused by meningitis (28% decrease), tetanus (78% decrease) among others (Fig. 4). During this 25-year period the total YLD for neurological disorders has increased in the 5-14 years olds, and only slightly decreased in the under 5 years.

Figure 4.

Figure 4

Years lived with disability of children (5-14 years) with neurological disorders from 1990-2015. (Color version of the figure available online.)

Most of the burden of neurological disorders occurs in the most populous parts of the world, namely Asia and Africa, both as total DALYs and as DALYs per capita, both for the under-fives (Fig. 5) and 5-14 year olds (Fig. 6). There are important regional differences. In the under 5 year olds, prematurity and neonatal encephalopathy have a higher prevalence of DALYs (per 100,000) in South Asia, compared other regions of the world, including sub-Saharan Africa. In the 5-14 years meningitis has the largest burden in sub-Saharan Africa; while in South Asia, encephalitis is greater (mainly due to Japanese encephalitis).

Figure 5.

Figure 5

DALYs per 100,000 in children aged less than 5 years across the regions of the world. Key HI, high income; MENA, Mediterranean and North Africa; sub-Sah Africa, sub-Saharan Africa. (Color version of the figure available online.)

Figure 6.

Figure 6

DALYs per 100,000 in children aged 5-14 years across the regions of the world. Key HI, high income; MENA, Mediterranean and North Africa; sub-Sah Africa, sub-Saharan Africa. (Color version of the figure available online.)

Limitations

The current estimates of the GBD provide a broad picture of the most common neurological conditions, but not accurate estimates of many neurological disorders, for example, many neuromuscular disorders or movement disorders.10 Some neurological conditions are difficult to disentangle from other major classes of diseases, for example, CNS infections from HIV and malaria, or traumatic brain injury from unintentional injuries, and stroke from sickle cell disease. The data from many regions is lacking, so that the GDB extrapolates from other regions, for example, the 2015 estimate of the DALY’s for autism spectrum disorders in Africa was not based on a single epidemiological study.

Conclusions

The global burden of neurological disorders in children is highest in Asia and sub-Saharan Africa. Many of the disorders originate during the perinatal period, and improved obstetrical care could significantly reduce this burden. The burden for years lived with disability in children aged 5-14 years has increased significantly over the last 25 years, highlighting the need for more support for expertise in the diagnosis and management of these disorders (for personnel and facilities), particularly in the under-resourced areas of the world.

References

  • 1.Murray CJ, Lopez AD. Quantifying disability: Data, methods and results. Bull World Health Organ. 1994;72:481–494. [PMC free article] [PubMed] [Google Scholar]
  • 2.Murray CJ. Quantifying the burden of disease: The technical basis for disability-adjusted life years. Bull World Health Organ. 1994;72:429–445. [PMC free article] [PubMed] [Google Scholar]
  • 3.DALYs GBD, Collaborators H. Murray CJ, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: Quantifying the epidemiological transition. Lancet. 2015;386:2145–2191. doi: 10.1016/S0140-6736(15)61340-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Erskine HE, Ferrari AJ, Polanczyk GV, et al. The global burden of conduct disorder and attention-deficit/hyperactivity disorder in 2010. J Child Psychol Psychiatry. doi: 10.1111/jcpp.12186. [DOI] [PubMed] [Google Scholar]
  • 5.Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: Disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012;380:2129–2143. doi: 10.1016/S0140-6736(12)61680-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Hawkins N, Scott DA. Cost-effectiveness analysis: discount the placebo at your peril. Med Decis Making. 2010;30:536–543. doi: 10.1177/0272989X10362106. [DOI] [PubMed] [Google Scholar]
  • 7.Holmes MW, Goodacre S, Stevenson MD, et al. The cost-effectiveness of diagnostic management strategies for children with minor head injury. Arch Dis Child. 2013;98:939–944. doi: 10.1136/archdischild-2012-302820. [DOI] [PubMed] [Google Scholar]
  • 8.Whiteford HA, Ferrari AJ, Degenhardt L, et al. The global burden of mental, neurological and substance use disorders: An analysis from the Global Burden of Disease Study 2010. PLoS ONE. 2015;10:e0116820. doi: 10.1371/journal.pone.0116820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.(IHME), I. f. H. M. a. E. GBDCompareDataVisualization. 2016. [Accessed January 2017]. Available from http://vizhub.healthdata.org/gbd-compare.
  • 10.Idro R, Newton C, Kiguli S, et al. Child neurology practice and neurological disorders in East Africa. J Child Neurol. 2010;25:518–524. doi: 10.1177/0883073809357792. [DOI] [PubMed] [Google Scholar]

RESOURCES